Neovacs
No short position is open on this share today.
0.00% of the capital sold short
0 disclosing funds
4 disclosures on record
Evolution of the disclosed total
0%1%
Oct 2025Jan 2026Apr 2026Jul 2026
January 15, 2021 today
Open positions
No fund discloses a short position on this share today. The History of disclosures table lists the ones that existed.
Get the moves on Neovacs by mail.
There is no account to create. You give an address, you confirm it through a link, and every message contains a link to stop.
History of disclosures
| Date | Fund | % of capital | End of publication | Filing |
|---|---|---|---|---|
| July 12, 2022 | Citadel Securities (Europe) Limited | 0.10% | July 14, 2022 | |
| June 8, 2022 | Citadel Securities (Europe) Limited | 0.69% | July 14, 2022 | |
| May 25, 2022 | Citadel Securities (Europe) Limited | 0.70% | July 14, 2022 | |
| January 15, 2021 | Renaissance Technologies LLC | 0.19% | January 20, 2021 | AMF |
The AMF column opens the filing the fund itself lodged, on the regulator own site.
Download 4 filings as CSV Columns: Date, Fund, Market, Disclosed position, Unit, End date. The other formats
Other companies sold short in France
- Ubisoft Entertainment 12.49% of the capital sold short
- Valeo 11.40% of the capital sold short
- Renault 9.16% of the capital sold short
- Viridien 8.08% of the capital sold short
- Teleperformance 7.58% of the capital sold short
- FDJ United 6.19% of the capital sold short
- Abivax 5.10% of the capital sold short
- Elis 4.91% of the capital sold short
- Alstom 4.57% of the capital sold short
- Rémy Cointreau 4.46% of the capital sold short
- Sopra Steria Group 3.92% of the capital sold short
- Spie SA 3.75% of the capital sold short
Cite this page
The figure comes from the regulator register, not from this site. Quoting both lets your reader check it.
QuiVad, Neovacs, source AMF, data as at July 12, 2022, https://www.quivad.com/action/neovacs